Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and its ligand (PD-L1), and inhibitors of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The introduction of immunoth...
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
Frontiers Media S.A.
2023-01-01
|
| Schriftenreihe: | Frontiers in Oncology |
| Schlagworte: | |
| Online Zugang: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1099304/full |